STOCK Nfkbiatm1Kbp Tg(KRT14-cre)1Cgn/Ieg

Status

Available to order

EMMA IDEM:06271
International strain nameSTOCK Nfkbiatm1Kbp Tg(KRT14-cre)1Cgn/Ieg
Alternative nameK14cre Ikba
Strain typeTransgenic Strains
Allele/Transgene symbolTg(KRT14-cre)1Cgn, Nfkbiatm1Kbp
Gene/Transgene symbolTg(KRT14-cre)1Cgn, Nfkbia

Information from provider

ProviderRudolf Rupec
Provider affiliationDerma AG
Genetic informationInducible skin specific deletion of Nfkbia (promoter region containing essential regulatory NF-kappaB binding sites, the core promoter, and the first two exons) with cre-loxP system. Cre-expression linked to keratin 14.
Phenotypic informationPersistent skin inflammation; psoriasis like.
References
  • Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin.;Rebholz Bernd, Haase Ingo, Eckelt Birgit, Paxian Stephan, Flaig Michael J, Ghoreschi Kamran, Nedospasov Sergei A, Mailhammer Reinhard, Debey-Pascher Svenja, Schultze Joachim L, Weindl Günther, Förster Irmgard, Huss Ralf, Stratis Athanasios, Ruzicka Thomas, Röcken Martin, Pfeffer Klaus, Schmid Roland M, Rupec Rudolf A, ;2007;Immunity;27;296-307; 17692539
  • Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha.;Rupec Rudolf A, Jundt Franziska, Rebholz Bernd, Eckelt Birgit, Weindl Günther, Herzinger Thomas, Flaig Michael J, Moosmann Sabine, Plewig Gerd, Dörken Bernd, Förster Irmgard, Huss Ralf, Pfeffer Klaus, ;2005;Immunity;22;479-91; 15845452
Homozygous fertileno
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisednot known

Information from EMMA

Archiving centreHelmholtz Zentrum Muenchen - German Research Center for Environmental Health (GmbH), Oberschleißheim, Germany
Animals used for archivingheterozygous C57BL/6N, wild-type C57BL/6N
Stage of embryos2-cell

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (gene matching)
  • increased leukocyte cell number / MGI
  • increased monocyte cell number / MGI
  • extramedullary hematopoiesis / MGI
  • abnormal erythropoiesis / MGI
  • increased bone marrow cell number / MGI
  • increased granulocyte number / MGI
  • small spleen / MGI
  • increased thymocyte number / MGI
  • decreased thymocyte number / MGI
  • reddish skin / MGI
  • abnormal skin condition / MGI
  • scaly skin / MGI
  • dermatitis / MGI
  • flaky skin / MGI
  • spontaneous skin ulceration / MGI
  • abnormal epidermis stratum basale morphology / MGI
  • abnormal epidermis stratum granulosum morphology / MGI
  • abnormal epidermis stratum corneum morphology / MGI
  • hyperkeratosis / MGI
  • decreased body weight / MGI
  • decreased body size / MGI
  • anemia / MGI
  • abnormal myelopoiesis / MGI
  • postnatal growth retardation / MGI
  • abnormal humoral immune response / MGI
  • decreased IgA level / MGI
  • abnormal T cell activation / MGI
  • increased activated T cell number / MGI
  • autoimmune response / MGI
  • acanthosis / MGI
  • premature death / MGI
  • abnormal B cell differentiation / MGI
  • no abnormal phenotype detected / MGI
  • abnormal granulocyte morphology / MGI
  • abnormal macrophage physiology / MGI
  • increased IgG level / MGI
  • increased IgA level / MGI
  • increased IgE level / MGI
  • chronic inflammation / MGI
  • abnormal keratinocyte morphology / MGI
  • increased anti-insulin autoantibody level / MGI
  • increased pre-B cell number / MGI
  • spleen atrophy / MGI
  • thymus atrophy / MGI
  • dry skin / MGI
  • increased anti-nuclear antigen antibody level / MGI
  • decreased regulatory T cell number / MGI
  • decreased B cell number / MGI
  • abnormal cell differentiation / MGI
  • decreased double-negative T cell number / MGI
  • increased double-positive T cell number / MGI
  • decreased double-positive T cell number / MGI
  • decreased B cell proliferation / MGI
  • decreased T cell proliferation / MGI
  • increased B cell proliferation / MGI
  • increased T cell proliferation / MGI
  • increased macrophage cell number / MGI
  • abnormal cell physiology / MGI
  • abnormal T cell number / MGI
  • increased T cell apoptosis / MGI
  • increased memory T cell number / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • increased single-positive T cell number / MGI
  • abnormal granulocyte differentiation / MGI
  • decreased Peyer's patch number / MGI
  • small Peyer's patches / MGI
  • decreased follicular B cell number / MGI
  • abnormal marginal zone B cell morphology / MGI
  • decreased marginal zone B cell number / MGI
  • increased pro-B cell number / MGI
  • decreased B-2 B cell number / MGI
  • decreased mature B cell number / MGI
  • increased immature B cell number / MGI
  • absent spleen germinal center / MGI
  • decreased IgG1 level / MGI
  • decreased IgG2b level / MGI
  • increased circulating tumor necrosis factor level / MGI
  • increased circulating interleukin-17 level / MGI
  • increased circulating interleukin-1 alpha level / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • decreased transitional stage T2 B cell number / MGI
  • abnormal circulating cytokine level / MGI
  • increased activation-induced B cell apoptosis / MGI
  • decreased CD4-positive, alpha-beta memory T cell number / MGI
  • postnatal lethality, complete penetrance / MGI

Literature references

  • Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin.;Rebholz Bernd, Haase Ingo, Eckelt Birgit, Paxian Stephan, Flaig Michael J, Ghoreschi Kamran, Nedospasov Sergei A, Mailhammer Reinhard, Debey-Pascher Svenja, Schultze Joachim L, Weindl Günther, Förster Irmgard, Huss Ralf, Stratis Athanasios, Ruzicka Thomas, Röcken Martin, Pfeffer Klaus, Schmid Roland M, Rupec Rudolf A, ;2007;Immunity;27;296-307; 17692539
  • Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha.;Rupec Rudolf A, Jundt Franziska, Rebholz Bernd, Eckelt Birgit, Weindl Günther, Herzinger Thomas, Flaig Michael J, Moosmann Sabine, Plewig Gerd, Dörken Bernd, Förster Irmgard, Huss Ralf, Pfeffer Klaus, ;2005;Immunity;22;479-91; 15845452

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).